+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Transplant Diagnostics Market - Global Forecast 2026-2032- Product Image
Transplant Diagnostics Market - Global Forecast 2026-2032- Product Image
Sale

Transplant Diagnostics Market - Global Forecast 2026-2032

  • Report

  • 186 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4986098
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Transplant Diagnostics Market is projected to reach USD 7.20 Billion in 2026. It is expected to continue growing at a CAGR of 7.03%, reaching USD 10.92 Billion by 2032.

Transplant diagnostics is a mission-critical segment of precision medicine, enabling safer organ allocation, donor-recipient compatibility assessment, immune risk stratification, and post-transplant monitoring. The field spans human leukocyte antigen (HLA) typing, antibody screening, crossmatching, chimerism testing, infectious disease testing, and emerging molecular tools such as next-generation sequencing (NGS), digital PCR, and donor-derived cell-free DNA assays.

Demand is anchored in measurable clinical need. The Global Observatory on Donation and Transplantation, supported by the World Health Organization and Organización Nacional de Trasplantes, reported more than 157,000 solid organ transplants worldwide in 2022, with kidney transplantation representing the largest procedure category. In the United States, the Health Resources and Services Administration and OPTN data consistently show more than 100,000 people on the national transplant waiting list, underscoring the persistent need for accurate transplant diagnostics that improve matching, reduce rejection risk, and support long-term graft survival.

Transformative Shifts in Transplant Diagnostics

The transplant diagnostics landscape is shifting from conventional serology-led testing toward integrated molecular, immunologic, and data-enabled workflows. HLA typing has moved from lower-resolution methods to high-resolution NGS in many advanced laboratories, improving allele-level characterization and helping clinicians identify immunologic risk with greater precision.

At the same time, transplant programs are expanding beyond pre-transplant compatibility testing. Post-transplant surveillance is gaining strategic importance as clinicians seek earlier signals of antibody-mediated rejection, cellular rejection, infection, and graft injury. Donor-derived cell-free DNA testing, noninvasive biomarker panels, and more standardized antibody monitoring are changing how laboratories, transplant centers, and diagnostics providers define value across the full transplant care continuum.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly relevant to transplant diagnostics because the field generates complex, high-dimensional data from HLA sequencing, antibody profiles, clinical histories, donor characteristics, pathology, imaging, and longitudinal graft monitoring. AI-enabled analytics can support faster interpretation of immunologic risk, improve pattern recognition in antibody data, and help prioritize clinically meaningful findings for transplant teams.

The cumulative impact of AI is expected to be operational as much as scientific. Laboratories can use machine learning-supported quality control, workflow triage, and decision-support tools to reduce manual review burden and improve turnaround time. However, adoption depends on transparent model validation, bias assessment, clinical governance, regulatory compliance, and interoperability with laboratory information systems and electronic health records.

Key Regional Insights: Global Transplant Diagnostics Demand

North America remains a leading region for transplant diagnostics due to established organ allocation infrastructure, advanced histocompatibility laboratories, reimbursement pathways for specialized molecular testing, and extensive clinical research activity. The United States is particularly influential through OPTN-governed allocation systems, large transplant volumes, and broad adoption of HLA typing, antibody testing, crossmatching, and molecular monitoring technologies, while Canada benefits from coordinated public transplant services and laboratory quality systems.

Europe benefits from mature transplant networks, national donation agencies, and cross-border collaboration, including Eurotransplant and national systems in the United Kingdom, Germany, France, Spain, and Italy. Asia-Pacific is expanding as China, India, Japan, South Korea, and Australia increase transplant capacity, improve laboratory accreditation, and invest in molecular diagnostics. Latin America, led by Brazil and Mexico, shows rising demand supported by public transplant programs, though access and funding remain uneven across health systems. The Middle East, especially GCC countries, is investing in tertiary care, organ donation frameworks, and transplant infrastructure, while Africa remains an emerging opportunity where diagnostic access, trained personnel, laboratory networks, and deceased donation systems are still developing.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

Within ASEAN, transplant diagnostics demand is shaped by expanding tertiary hospitals, medical tourism in selected markets, and gradual investment in HLA typing, crossmatching, antibody screening, and infectious disease testing capabilities. The GCC is prioritizing advanced healthcare infrastructure, national transplant programs, and specialized laboratories, creating demand for high-quality immunogenetics, molecular diagnostics, and post-transplant monitoring services.

The European Union offers a strong regulatory and clinical environment for validated transplant testing, supported by harmonized quality expectations, mature donation systems, and cross-border clinical collaboration. BRICS countries represent a strategically important group because of large patient populations, rising chronic kidney disease burden, and investment in transplant capacity, although reimbursement, accreditation, and diagnostic access vary widely. G7 countries lead in technology adoption, clinical research, automation, NGS-based HLA typing, and noninvasive graft monitoring, while NATO member states overlap significantly with advanced healthcare systems that rely on resilient diagnostics supply chains, standardized laboratory practices, and interoperable transplant data systems.

Key Country Insights Across Major Transplant Diagnostics Markets

The United States leads transplant diagnostics adoption through high transplant activity, strong laboratory infrastructure, and broad use of HLA typing, antibody identification, virtual crossmatching, and post-transplant monitoring. Canada maintains strong public healthcare coordination and advanced transplant programs, while Mexico is expanding access through national and regional transplant initiatives. Brazil is Latin America’s largest transplant system by procedural scale, supported by a public donation and transplant framework and growing demand for histocompatibility testing.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are core markets due to organized donation systems, high clinical standards, and established histocompatibility laboratories; Spain is especially recognized for its world-leading deceased donation model. Russia has specialized transplant capabilities but faces uneven regional access and infrastructure variability. In Asia-Pacific, China and India offer significant long-term expansion potential due to population scale, chronic kidney disease burden, and increasing transplant capacity; Japan has sophisticated diagnostics adoption within a highly regulated system, Australia maintains advanced transplant services and national coordination, and South Korea combines strong hospital infrastructure with rapid molecular diagnostics uptake.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated, end-to-end transplant diagnostics portfolios that connect pre-transplant compatibility, peri-transplant risk assessment, and post-transplant surveillance. Providers that combine HLA typing, antibody testing, molecular monitoring, automation, and data interpretation will be better positioned to support transplant centers seeking actionable results rather than isolated test outputs.

Strategic priorities include expanding NGS-based HLA capabilities, strengthening evidence for donor-derived cell-free DNA and other noninvasive biomarkers, improving laboratory workflow automation, and building interoperable software for longitudinal patient monitoring. Organizations should also invest in regional access strategies, distributor quality management, clinical education, and partnerships with transplant networks to demonstrate outcomes such as reduced rejection risk, improved graft monitoring, and faster decision-making.

Research Methodology

This executive summary is developed using a structured secondary research approach and expert synthesis. Verified sources include public transplant activity data from the Global Observatory on Donation and Transplantation, WHO-associated reporting, OPTN and HRSA resources, national transplant agencies, peer-reviewed transplantation journals, regulatory guidance, and publicly available healthcare system disclosures.

The methodology emphasizes data triangulation across procedure volumes, diagnostic adoption patterns, clinical guidelines, technology trends, reimbursement signals, and regional healthcare infrastructure. Insights were assessed for consistency, recency, and relevance to transplant diagnostics, with emphasis on evidence-backed developments in HLA typing, antibody monitoring, crossmatching, molecular diagnostics, noninvasive graft surveillance, and AI-enabled laboratory workflows.

Conclusion: Precision Diagnostics Will Define Transplant Outcomes

The transplant diagnostics market is evolving from episodic compatibility testing into a broader precision transplant management ecosystem. Rising transplant demand, persistent organ shortages, increasing immunologic complexity, and the need for improved graft survival are reinforcing the strategic value of advanced diagnostics.

Organizations that deliver validated molecular tools, faster laboratory workflows, integrated data interpretation, and clinically meaningful surveillance solutions are positioned to strengthen competitive relevance. As healthcare systems focus on measurable outcomes, transplant diagnostics will remain essential to organ allocation, rejection prevention, patient monitoring, and long-term transplant success.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Transplant Diagnostics Market, by Diagnostic Application
7.1. Introduction
7.2. Donor Recipient Matching
7.3. Graft Monitoring
7.4. Hla Typing
7.4.1. High Resolution
7.4.2. Low Resolution
7.5. Infectious Disease Screening
7.5.1. Bacterial Screening
7.5.2. Fungal Screening
7.5.3. Viral Screening
7.5.3.1. Cytomegalovirus
7.5.3.2. Epstein Barr Virus
7.5.3.3. Hepatitis Viruses
7.5.3.4. Hiv
8. Transplant Diagnostics Market, by Technology
8.1. Introduction
8.2. Enzymatic Assays
8.3. Flow Cytometry
8.4. Pcr
8.4.1. Digital Pcr
8.4.2. Qpcr
8.5. Sequencing
8.5.1. Next Generation
8.5.2. Sanger
9. Transplant Diagnostics Market, by Organ Type
9.1. Introduction
9.2. Heart
9.3. Kidney
9.4. Liver
9.5. Lung
9.6. Pancreas
10. Transplant Diagnostics Market, by End User
10.1. Introduction
10.2. Diagnostic Laboratories
10.3. Hospitals
10.3.1. Private Hospitals
10.3.2. Public Hospitals
10.4. Research Institutes
10.5. Transplant Centers
11. Transplant Diagnostics Market, by Region
11.1. Asia-Pacific
11.2. North America
11.3. Latin America
11.4. Europe
11.5. Middle East
11.6. Africa
12. Transplant Diagnostics Market, by Group
12.1. ASEAN
12.2. GCC
12.3. European Union
12.4. BRICS
12.5. G7
12.6. NATO
13. Transplant Diagnostics Market, by Country
13.1. United States
13.2. Canada
13.3. Mexico
13.4. Brazil
13.5. United Kingdom
13.6. Germany
13.7. France
13.8. Russia
13.9. Italy
13.10. Spain
13.11. China
13.12. India
13.13. Japan
13.14. Australia
13.15. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. FPNV Positioning Matrix, 2025
14.3. Market Concentration Analysis, 2025
14.3.1. Concentration Ratio (CR)
14.3.2. Herfindahl Hirschman Index (HHI)
14.4. Recent Developments & Impact Analysis, 2025
14.5. Product Portfolio Analysis, 2025
14.6. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Abbott Laboratories
15.2. Adaptive Biotechnologies Corporation
15.3. altona Diagnostics GmbH
15.4. Arquer Diagnostics Ltd.
15.5. BAG Group
15.6. Becton, Dickinson and Company
15.7. Bio-Rad Laboratories, Inc.
15.8. Biogenuix Medsystems Pvt. Ltd
15.9. BioMérieux SA
15.10. Bruker Corporation
15.11. Caredx Inc.
15.12. CareDx, Inc.
15.13. CLONIT srl
15.14. Diagnóstica Longwood SL
15.15. DiaSorin S.p.A.
15.16. Eurofins Scientific SE
15.17. F. Hoffmann-La Roche Ltd.
15.18. Genome Diagnostics B.V.
15.19. Hologic, Inc.
15.20. Illumina, Inc
15.21. Immucor, Inc.
15.22. Laboratory Corporation of America Holdings
15.23. Luminex Corporation
15.24. Merck KGaA
15.25. NanoString Technologies, Inc.
15.26. Novartis AG
15.27. PathoNostics B.V
15.28. QIAGEN, N.V.
15.29. Quest Diagnostics Incorporated
15.30. Randox Laboratories Ltd.
15.31. Takara Bio Inc.
15.32. Thermo Fisher Scientific Inc.
15.33. TransMedics, Inc.
15.34. Zimmer Biomet Group
List of Figures
FIGURE 1. GLOBAL TRANSPLANT DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL TRANSPLANT DIAGNOSTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL TRANSPLANT DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL TRANSPLANT DIAGNOSTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 9. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 17. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 19. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 21. GLOBAL TRANSPLANT DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL DONOR RECIPIENT MATCHING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL DONOR RECIPIENT MATCHING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL DONOR RECIPIENT MATCHING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL GRAFT MONITORING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL GRAFT MONITORING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL GRAFT MONITORING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL HLA TYPING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL HLA TYPING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL HLA TYPING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL HIGH RESOLUTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL HIGH RESOLUTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL HIGH RESOLUTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL LOW RESOLUTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL LOW RESOLUTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL LOW RESOLUTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL INFECTIOUS DISEASE SCREENING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL INFECTIOUS DISEASE SCREENING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL INFECTIOUS DISEASE SCREENING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL BACTERIAL SCREENING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL BACTERIAL SCREENING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL BACTERIAL SCREENING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL FUNGAL SCREENING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL FUNGAL SCREENING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL FUNGAL SCREENING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL VIRAL SCREENING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL VIRAL SCREENING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL VIRAL SCREENING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL CYTOMEGALOVIRUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL CYTOMEGALOVIRUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL CYTOMEGALOVIRUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL EPSTEIN BARR VIRUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL EPSTEIN BARR VIRUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL EPSTEIN BARR VIRUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL HEPATITIS VIRUSES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL HEPATITIS VIRUSES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL HEPATITIS VIRUSES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL HIV MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL HIV MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL HIV MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL ENZYMATIC ASSAYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL ENZYMATIC ASSAYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL ENZYMATIC ASSAYS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL PCR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL PCR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL PCR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL DIGITAL PCR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL DIGITAL PCR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL DIGITAL PCR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL QPCR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL QPCR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL QPCR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL NEXT GENERATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL NEXT GENERATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL NEXT GENERATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL SANGER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL SANGER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL SANGER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL HEART MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL HEART MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL HEART MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL KIDNEY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL KIDNEY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL KIDNEY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL LIVER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL LIVER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL LIVER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL LUNG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL LUNG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL LUNG MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL PANCREAS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL PANCREAS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL PANCREAS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL TRANSPLANT CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL TRANSPLANT CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL TRANSPLANT CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2017-2032 (USD MILLION)
TABLE 106. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2017-2032 (USD MILLION)
TABLE 107. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2017-2032 (USD MILLION)
TABLE 108. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2017-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2017-2032 (USD MILLION)
TABLE 111. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2017-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2017-2032 (USD MILLION)
TABLE 113. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 115. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2017-2032 (USD MILLION)
TABLE 117. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2017-2032 (USD MILLION)
TABLE 118. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2017-2032 (USD MILLION)
TABLE 119. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2017-2032 (USD MILLION)
TABLE 120. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 121. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2017-2032 (USD MILLION)
TABLE 122. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2017-2032 (USD MILLION)
TABLE 123. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2017-2032 (USD MILLION)
TABLE 124. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 125. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 126. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 127. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2017-2032 (USD MILLION)
TABLE 128. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2017-2032 (USD MILLION)
TABLE 129. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2017-2032 (USD MILLION)
TABLE 130. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2017-2032 (USD MILLION)
TABLE 131. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 132. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2017-2032 (USD MILLION)
TABLE 133. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2017-2032 (USD MILLION)
TABLE 134. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2017-2032 (USD MILLION)
TABLE 135. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 136. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 137. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 138. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2017-2032 (USD MILLION)
TABLE 139. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2017-2032 (USD MILLION)
TABLE 140. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2017-2032 (USD MILLION)
TABLE 141. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2017-2032 (USD MILLION)
TABLE 142. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 143. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2017-2032 (USD MILLION)
TABLE 144. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2017-2032 (USD MILLION)
TABLE 145. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2017-2032 (USD MILLION)
TABLE 146. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 147. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 148. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 149. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2017-2032 (USD MILLION)
TABLE 150. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2017-2032 (USD MILLION)
TABLE 151. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2017-2032 (USD MILLION)
TABLE 152. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2017-2032 (USD MILLION)
TABLE 153. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 154. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2017-2032 (USD MILLION)
TABLE 155. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2017-2032 (USD MILLION)
TABLE 156. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2017-2032 (USD MILLION)
TABLE 157. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 158. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 159. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 160. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2017-2032 (USD MILLION)
TABLE 161. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2017-2032 (USD MILLION)
TABLE 162. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2017-2032 (USD MILLION)
TABLE 163. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2017-2032 (USD MILLION)
TABLE 164. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 165. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2017-2032 (USD MILLION)
TABLE 166. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2017-2032 (USD MILLION)
TABLE 167. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2017-2032 (USD MILLION)
TABLE 168. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 169. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 170. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 171. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 172. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2017-2032 (USD MILLION)
TABLE 173. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2017-2032 (USD MILLION)
TABLE 174. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2017-2032 (USD MILLION)
TABLE 175. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2017-2032 (USD MILLION)
TABLE 176. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 177. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2017-2032 (USD MILLION)
TABLE 178. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2017-2032 (USD MILLION)
TABLE 179. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2017-2032 (USD MILLION)
TABLE 180. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 181. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 182. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 183. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2017-2032 (USD MILLION)
TABLE 184. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2017-2032 (USD MILLION)
TABLE 185. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2017-2032 (USD MILLION)
TABLE 186. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2017-2032 (USD MILLION)
TABLE 187. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 188. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2017-2032 (USD MILLION)
TABLE 189. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2017-2032 (USD MILLION)
TABLE 190. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2017-2032 (USD MILLION)
TABLE 191. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 192. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2017-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2017-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2017-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2017-2032 (USD MILLION)
TABLE 198. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 199. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2017-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2017-2032 (USD MILLION)
TABLE 201. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2017-2032 (USD MILLION)
TABLE 202. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 203. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 204. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 205. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2017-2032 (USD MILLION)
TABLE 206. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2017-2032 (USD MILLION)
TABLE 207. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2017-2032 (USD MILLION)
TABLE 208. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2017-2032 (USD MILLION)
TABLE 209. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 210. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2017-2032 (USD MILLION)
TABLE 211. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2017-2032 (USD MILLION)
TABLE 212. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2017-2032 (USD MILLION)
TABLE 213. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 214. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 215. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 216. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2017-2032 (USD MILLION)
TABLE 217. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2017-2032 (USD MILLION)
TABLE 218. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2017-2032 (USD MILLION)
TABLE 219. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2017-2032 (USD MILLION)
TABLE 220. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 221. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2017-2032 (USD MILLION)
TABLE 222. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2017-2032 (USD MILLION)
TABLE 223. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2017-2032 (USD MILLION)
TABLE 224. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 225. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 226. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 227. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2017-2032 (USD MILLION)
TABLE 228. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2017-2032 (USD MILLION)
TABLE 229. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2017-2032 (USD MILLION)
TABLE 230. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2017-2032 (USD MILLION)
TABLE 231. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 232. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2017-2032 (USD MILLION)
TABLE 233. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2017-2032 (USD MILLION)
TABLE 234. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2017-2032 (USD MILLION)
TABLE 235. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 236. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 237. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 238. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 239. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2017-2032 (USD MILLION)
TABLE 240. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2017-2032 (USD MILLION)
TABLE 241. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2017-2032 (USD MILLION)
TABLE 242. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2017-2032 (USD MILLION)
TABLE 243. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 244. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2017-2032 (USD MILLION)
TABLE 245. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2017-2032 (USD MILLION)
TABLE 246. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2017-2032 (USD MILLION)
TABLE 247. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 248. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 249. CANADA TRANSPLANT DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 250. CANADA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2017-2032 (USD MILLION)
TABLE 251. CANADA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2017-2032 (USD MILLION)
TABLE 252. CANADA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2017-2032 (USD MILLION)
TABLE 253. CANADA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2017-2032 (USD MILLION)
TABLE 254. CANADA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 255. CANADA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2017-2032 (USD MILLION)
TABLE 256. CANADA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2017-2032 (USD MILLION)
TABLE 257. CANADA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2017-2032 (USD MILLION)
TABLE 258. CANADA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 259. CANADA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 260. MEXICO TRANSPLANT DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 261. MEXICO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2017-2032 (USD MILLION)
TABLE 262. MEXICO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2017-2032 (USD MILLION)
TABLE 263. MEXICO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2017-2032 (USD MILLION)
TABLE 264. MEXICO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2017-2032 (USD MILLION)
TABLE 265. MEXICO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 266. MEXICO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2017-2032 (USD MILLION)
TABLE 267. MEXICO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2017-2032 (USD MILLION)
TABLE 268. MEXICO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2017-2032 (USD MILLION)
TABLE 269. MEXICO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 270. MEXICO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 271. BRAZIL TRANSPLANT DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 272. BRAZIL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2017-2032 (USD MILLION)
TABLE 273. BRAZIL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2017-2032 (USD MILLION)
TABLE 274. BRAZIL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2017-2032 (USD MILLION)
TABLE 275. BRAZIL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2017-2032 (USD MILLION)
TABLE 276. BRAZIL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 277. BRAZIL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2017-2032 (USD MILLION)
TABLE 278. BRAZIL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2017-2032 (USD MILLION)
TABLE 279. BRAZIL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2017-2032 (USD MILLION)
TABLE 280. BRAZIL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 281. BRAZIL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 282. UNITED KINGDOM TRANSPLANT DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 283. UNITED KINGDOM TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2017-2032 (USD MILLION)
TABLE 284. UNITED KINGDOM TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2017-2032 (USD MILLION)
TABLE 285. UNITED KINGDOM TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2017-2032 (USD MILLION)
TABLE 286. UNITED KINGDOM TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2017-2032 (USD MILLION)
TABLE 287. UNITED KINGDOM TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 288. UNITED KINGDOM TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2017-2032 (USD MILLION)
TABLE 289. UNITED KINGDOM TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2017-2032 (USD MILLION)
TABLE 290. UNITED KINGDOM TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2017-2032 (USD MILLION)
TABLE 291. UNITED KINGDOM TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 292. UNITED KINGDOM TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 293. GERMANY TRANSPLANT DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 294. GERMANY TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2017-2032 (USD MILLION)
TABLE 295. GERMANY TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2017-2032 (USD MILLION)
TABLE 296. GERMANY TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2017-2032 (USD MILLION)
TABLE 297. GERMANY TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2017-2032 (USD MILLION)
TABLE 298. GERMANY TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 299. GERMANY TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2017-2032 (USD MILLION)
TABLE 300. GERMANY TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2017-2032 (USD MILLION)
TABLE 301. GERMANY TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2017-2032 (USD MILLION)
TABLE 302. GERMANY TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 303. GERMANY TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 304. FRANCE TRANSPLANT DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 305. FRANCE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2017-2032 (USD MILLION)
TABLE 306. FRANCE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2017-2032 (USD MILLION)
TABLE 307. FRANCE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2017-2032 (USD MILLION)
TABLE 308. FRANCE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2017-2032 (USD MILLION)
TABLE 309. FRANCE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 310. FRANCE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2017-2032 (USD MILLION)
TABLE 311. FRANCE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2017-2032 (USD MILLION)
TABLE 312. FRANCE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2017-2032 (USD MILLION)
TABLE 313. FRANCE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 314. FRANCE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 315. RUSSIA TRANSPLANT DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 316. RUSSIA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2017-2032 (USD MILLION)
TABLE 317. RUSSIA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2017-2032 (USD MILLION)
TABLE 318. RUSSIA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2017-2032 (USD MILLION)
TABLE 319. RUSSIA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2017-2032 (USD MILLION)
TABLE 320. RUSSIA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 321. RUSSIA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2017-2032 (USD MILLION)
TABLE 322. RUSSIA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2017-2032 (USD MILLION)
TABLE 323. RUSSIA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2017-2032 (USD MILLION)
TABLE 324. RUSSIA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 325. RUSSIA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 326. ITALY TRANSPLANT DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 327. ITALY TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2017-2032 (USD MILLION)
TABLE 328. ITALY TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2017-2032 (USD MILLION)
TABLE 329. ITALY TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2017-2032 (USD MILLION)
TABLE 330. ITALY TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2017-2032 (USD MILLION)
TABLE 331. ITALY TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 332. ITALY TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2017-2032 (USD MILLION)
TABLE 333. ITALY TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2017-2032 (USD MILLION)
TABLE 334. ITALY TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2017-2032 (USD MILLION)
TABLE 335. ITALY TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 336. ITALY TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 337. SPAIN TRANSPLANT DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 338. SPAIN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2017-2032 (USD MILLION)
TABLE 339. SPAIN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2017-2032 (USD MILLION)
TABLE 340. SPAIN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2017-2032 (USD MILLION)
TABLE 341. SPAIN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2017-2032 (USD MILLION)
TABLE 342. SPAIN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 343. SPAIN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2017-2032 (USD MILLION)
TABLE 344. SPAIN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2017-2032 (USD MILLION)
TABLE 345. SPAIN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2017-2032 (USD MILLION)
TABLE 346. SPAIN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 347. SPAIN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 348. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 349. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2017-2032 (USD MILLION)
TABLE 350. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2017-2032 (USD MILLION)
TABLE 351. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2017-2032 (USD MILLION)
TABLE 352. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2017-2032 (USD MILLION)
TABLE 353. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 354. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2017-2032 (USD MILLION)
TABLE 355. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2017-2032 (USD MILLION)
TABLE 356. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2017-2032 (USD MILLION)
TABLE 357. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 358. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 359. INDIA TRANSPLANT DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 360. INDIA TRANSPLANT DIAGNOSTIC

Companies Mentioned

  • Abbott Laboratories
  • Adaptive Biotechnologies Corporation
  • altona Diagnostics GmbH
  • Arquer Diagnostics Ltd.
  • BAG Group
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biogenuix Medsystems Pvt. Ltd
  • BioMérieux SA
  • Bruker Corporation
  • Caredx Inc.
  • CareDx, Inc.
  • CLONIT srl
  • Diagnóstica Longwood SL
  • DiaSorin S.p.A.
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd.
  • Genome Diagnostics B.V.
  • Hologic, Inc.
  • Illumina, Inc
  • Immucor, Inc.
  • Laboratory Corporation of America Holdings
  • Luminex Corporation
  • Merck KGaA
  • NanoString Technologies, Inc.
  • Novartis AG
  • PathoNostics B.V
  • QIAGEN, N.V.
  • Quest Diagnostics Incorporated
  • Randox Laboratories Ltd.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • TransMedics, Inc.
  • Zimmer Biomet Group

Table Information

Report AttributeDetails
No. of Pages186
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 7.2 Billion
Forecasted Market Value ( USD ) by 2032 $ 10.92 Billion
Compound Annual Growth Rate7.0%
Regions CoveredGlobal
No. of Companies Mentioned34

Related Topics

Related Reports

Transplant Diagnostics - Global Strategic Business Report - Product Image

Transplant Diagnostics - Global Strategic Business Report

  • Report
  • 533 Pages
  • Global
From
Transplant Diagnostics Market Report Size, Share, Trends and Forecast by Component, Technology, Organ Type, Application, End User, and Region, 2026-2034 - Product Image

Transplant Diagnostics Market Report Size, Share, Trends and Forecast by Component, Technology, Organ Type, Application, End User, and Region, 2026-2034

  • Report
  • 146 Pages
  • Global
From
Transplant Diagnostics Market Forecast to 2033 - Product Image

Transplant Diagnostics Market Forecast to 2033

  • Report
  • 150 Pages
  • Global
From
Serological Transplant Diagnostics - Global Strategic Business Report - Product Image

Serological Transplant Diagnostics - Global Strategic Business Report

  • Report
  • 161 Pages
  • Global
From
Transplant Diagnostics Market by Product & Service, Technology, Application, Type, End User & Region - Global Forecast to 2031 - Product Image

Transplant Diagnostics Market by Product & Service, Technology, Application, Type, End User & Region - Global Forecast to 2031

  • Report
  • 254 Pages
  • Global
From

About the Transplant Diagnostics Market

The Transplant Diagnostics market is a subset of the Diagnostics industry, which focuses on the development and commercialization of tests and technologies used to diagnose and monitor transplant patients. These tests are used to detect and monitor the presence of donor-derived cells, as well as to assess the risk of rejection and other complications. Transplant Diagnostics also includes tests used to detect and monitor infections, such as viruses and bacteria, that can be transmitted through transplanted organs. The Transplant Diagnostics market is driven by the increasing number of organ transplants, as well as the need for improved patient outcomes. Additionally, the development of new technologies and tests, such as next-generation sequencing and mass spectrometry, has enabled more accurate and timely diagnosis and monitoring of transplant patients. Some companies in the Transplant Diagnostics market include Abbott, Bio-Rad Laboratories, Becton Dickinson, Cepheid, and Roche Diagnostics. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.